The global prefilled syringes market size was estimated at USD 8.01 billion in 2024 and is projected to grow at a CAGR of 13.50% from 2025 to 2030. Factors driving the market growth include rising prevalence of chronic diseases, growing adoption of self-injection devices, technological advancements. Additionally, supportive government regulations, increased demand for biologics and biosimilars, and rising shift towards home healthcare are augmenting the market growth. However, stringent government regulations and availability of cheaper alternatives are hindering the market growth.
The rising frequency of chronic diseases and the increasing adoption of self-administered biologics for chronic conditions such as diabetes and auto-immune diseases through the mediums of prefilled syringes, are enhancing growth worldwide in prefilled syringes market. The global elderly population is predicted to increase demand for prefilled syringes. This is due to elderly people are more susceptible to numerous chronic conditions and frequently require healthcare assistance. Approximately 70% of the rheumatoid arthritis patients are female. The symptoms usually begin somewhere between the ages of 30 to 50, though it is possible for them to occur in people of all ages. There are various treatment options for managing symptoms associated with rheumatoid arthritis; for instance, 1mL UniSafe syringes from Owen Mumford have received regulatory approval in Europe, and the medicine is currently available on the market as a combination product with a rheumatoid arthritis drug.
Regulatory bodies like the U.S., FDA, and the EU are actively contributing to industry expansion in market by the increasing numbers of approvals for prefilled syringes., For instance, 1mL UniSafe, product from Owen Mumford Pharmaceutical Services Limited was approved as a combination product in Asian countries in September 2022. 1mL. 1ml UniSafe is an innovative, patented and spring-less safety mechanism for pre-filled syringes and delivers numerous benefits both to pharmaceuticals companies and their patients; In addition, the FDA also claims that 55% of FDA drug approvals in 2021 were accounted for injectables and mentioned the ten-year high in non-new molecular entity (NME) injectables approvals happened in 2022. which is anticipated to increase the demand for prefilled syringes in the near future.
A steep rise in the development of biological therapies is expected to boost growth of the prefilled syringes industry. Biologic drugs including therapeutic vaccines are rapidly replacing the traditional therapeutic options owing to their increased efficiency, efficacy as well as patient safety with reduced side effects. The constant introduction of biologic drugs has given rise to the demand for innovative packaging solutions to maintain the potency of these drugs as they are extremely unstable. More than 60% of the biologic drugs are currently in the pipeline and preferred with parenteral administration as any interaction with food and digestive enzymes results in their deterioration. Thus, prefilled syringes are considered to be an ideal container for the storage of such drugs. Moreover, the growth of the biologic drug market has a direct positive impact on the market.
The prefilled syringes market is considered moderately concentrated, with a mix of large, established players and a growing number of niche players. There is a constant push for innovation in prefilled syringe design and functionality. This includes the development of new materials, safety features, and combination devices for self-injection
The market shows a moderate to high degree of innovation. For instance, in March 2024, Biocon Biologics has been given a deadline to launch their YESAFILI medication by July 1, 2025. This 2mg dose will be available in both vials and pre-filled syringes.
Prefilled syringes are classified as medical devices and subject to strict regulations by governing bodies like the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This ensures patient safety and product quality.
M&A activity is likely focused on strategic acquisitions rather than large-scale mergers. This means established players might acquire smaller companies with specific technologies or regional presence to expand their offerings or reach. For instance, in February 2024, Novo Nordisk's investment arm, Novo Holdings, is set to buy Catalent, a contract drug manufacturer, in a $16.5 billion cash deal.
Product substitutes include vials and ampoules, pen injectors and autoinjectors. Autoinjectors are prefilled, single-use devices are designed for self-administration of medication. They offer convenience and ease of use but are typically more expensive than prefilled syringes and limited in terms of medication types and dosages.
The prefilled syringes industry is experiencing significant regional expansion. Manufacturers are increasingly setting up production facilities in emerging markets to reduce costs and improve supply chain efficiency. For instance, in May 2022, SCHOTT boosts production of next-generation syringes. Their new German plant focuses on prefilled syringes made from innovative polymers, ideal for various medications including mRNA drugs.
The disposable segment accounted for the largest market share of 91.5% in 2024 and shows the fastest CAGR over the forecast period. Growing self-injecting medication brings need for safety while using syringes, whereas nowadays, with the advent of disposable syringes it is much easier to eliminate the risk to a certain extent, by throwing away the needle immediately after the use of injection so that no cross contamination occurs. Disposable prefilled syringes are required for most diagnostic and therapeutic approaches for chronic diseases since they are essential during medication administration and tests, resulting in rising demand for the product. In June 2021, Hindustan Syringes and Medical Devices Ltd. entered a technical collaboration with Star Syringes of the UK to launch disposable safety needles with sharps injury prevention under the Disposjekt Needle brand.
The reusable segment held a significant market share in 2024. Some syringes can be used more than one time on a patient with disposable tips. This can help manufacturers and healthcare personnel in reducing costs and the possibility of infections if safety protocols are followed correctly. Substituting an auto-injector for using once-a-week reusable injections is likely to generate savings of as much as 200 units per year in production requirements. For instance, according to U.S. FDA in October 2019, manufacturers commonly provide dental dispensers as prefilled syringes with disposable tips. While the tips are discarded after each patient, the dispensers with remaining dental material are often reused.
The glass segment accounted for the largest market share of 50.4% in 2024. Glass acts as a strong barrier against external elements like moisture, oxygen, and light. This is essential for protecting the medication from degradation and ensuring its stability over time. While some plastics offer good barrier properties, they might not be as effective as glass for all medications, especially those sensitive to specific environmental factors. Additionally, glass syringes offer excellent clarity, allowing healthcare providers to easily visualize the medication inside.
The plastic segment held significant market share in 2024. Compared to glass syringes, plastic offers a more economical option due to lower material and manufacturing costs. This affordability is crucial for making prefilled syringes accessible in various healthcare settings, particularly in emerging markets. Plastic offers greater design flexibility compared to glass. This allows for the development of innovative features like multi-chamber syringes or integrated needle guards, enhancing functionality and safety. This advantages associated with plastic prefilled syringes is anticipated to fuel the demand for plastic prefilled syringes.
The vaccines and immunizations segment accounted for the largest market share of 25.9% in 2024. Numerous vaccines require multiple doses to be administered over a period of time. Prefilled syringes are perfect for this purpose as they eliminate the need for healthcare providers to draw medication from vials, reducing the risk of errors and contamination. Prefilled syringes are easier for patients to use than traditional vials and syringes. This can lead to improved patient compliance, which is essential for the success of vaccination programs. For instance, prefilled syringes can be pre-measured and labeled, making them easier for patients to self-administer at home.
The oncology segment is projected to witness the fastest CAGR over the forecast period.Many oncology treatments involve frequent injections, and prefilled syringes offer significant advantages for patients undergoing chemotherapy or other injectable therapies. They are easier to transport and self-administer compared to traditional vials and syringes, improving patient comfort and independence during treatment. Advancements in prefilled syringe technology, such as multi-chamber syringes, are facilitating the delivery of combination therapies used in some cancer treatment regimens. These features offer greater flexibility and convenience for both patients and healthcare providers.
The hospitals segment accounted for the largest market share of 51.5% in 2024. Hospitals are often the preferred choice for patients seeking treatment due to their convenient accessibility and established trust. Patients can also visit hospital for seeking fluid therapy which administer fluids to patients’ body intravenously. Furthermore, the Centers for Disease Control and Prevention (CDC) estimates that 60-88 % sharps-related injuries can be lowered by using safety measures as of such as prefilled syringes.
The mail order pharmacies segment is projected to grow at the fastest CAGR over the forecast period.Mail order pharmacies offer patients increased convenience by delivering medications directly to their homes. This can be particularly beneficial for patients who require regular injections with prefilled syringes, eliminating the need for frequent trips to the pharmacy. They also offer competitive pricing on medications and potentially lower overall healthcare costs. This can be particularly attractive for patients with chronic conditions who require ongoing treatment with prefilled syringes. Such advantages associated with mail order pharmacies is projected to rise its CAGR over the forecast period.
North America prefilled syringes market accounted for the 32.0% revenue share in 2024. Preventing needlestick injuries among healthcare professionals is a major priority in developed nations, including the U.S. and Canada. Prefilled syringes with needle guards decrease the possibility of these injuries becoming increasingly prevalent owing to this concern. Prefilled syringes are recommended by the U.S. Centers for Disease Control for vaccine administration owing to their ability to preserve vaccine potency over long storage periods and their ability to save time which is driving the market growth.
The prefilled syringes industry in the U.S. held a significant share of North America in 2024. Various factors spur the U.S. market growth, such as the rising incidences of lifestyle-related illnesses and patients with chronic disorders' increasing need for simple injectables. Moreover, the increased use of auto-injector devices, well-developed pharmaceutical systems, technological advancements, self-administered equipment for patients' routine prescription doses, and recommendations by the Centers for Disease Control and Prevention (CDC) are expected to drive market growth.
The prefilled syringes industry in Europe dominated the overall global market and is driven by the strong preference of medical professionals for injectable devices that are prefilled to reduce damage caused by needles. Prominent players in the region's market and several government initiatives to enforce the usage of single-use medical goods to prevent infections are anticipated to contribute to the region's growth.
The UK prefilled syringes market is driven by several factors, including the increasing prevalence of chronic diseases such as diabetes, the growing aging population, and the adoption of biosimilars are driving the market growth. Technological advancements, the introduction of new products, and the growing use of prefilled syringes are the main drivers of the segment's growth. For instance, in March 2022, Novo Nordisk introduced its smart insulin pens in the UK, and patients receiving care for diabetes under the National Health Service (NHS) were provided with access to devices that could record and monitor dosage information for the first time.
The prefilled syringes market in France is thriving owing to several key drivers. Prefilled syringes are designed to provide accurate dosing, reducing the risk of dosing errors. They are user-friendly and minimize the need for manual preparation, making them a safer and more convenient option for both healthcare professionals and patients in France and provides essential funding and incentives for research.
The Germany prefilled syringes market is expected to expand in the foreseeable future. The prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis is increasing in Germany. Prefilled syringes are a preferred choice for self-administration of these medications, contributing to market growth. For instance, in August 2021, the German specialty glass company SCHOTT AG and its most recent partner, Serum Institute of India, acquired a 50% share in the joint venture SCHOTT Kaisha in India.
The prefilled syringes industry in Asia Pacific region is projected to experience notable expansion owing to the availability of a significant number of Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA), and European Medicines Agency (EMA)-approved facilities in the region. Additionally, the region's rapidly developing economy and massive unexplored market is anticipated to increase owing to favorable demographic variables such as high population and an increasing frequency of numerous chronic conditions.
The Japan prefilled syringes market is poised for substantial growth, as Japan's aging population has increased the prevalence of chronic diseases, patient’s safety and convenience. In addition, regulatory reforms and incentives, biologics and biosimilars and fast-track approval processes, have attracted pharmaceutical companies to invest in prefilled syringes in Japan.
The prefilled syringes market in China is influenced by several market drivers, contributing to the growth and adoption of these medical devices. China's rapidly evolving healthcare landscape and patient needs played a significant role in driving the market growth. China has witnessed a growing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and autoimmune disorders.
The India prefilled syringes market’s growth is driven by several factors, including a large and genetically diverse population, cost-effective infrastructure, a pool of experienced medical professionals, favorable regulatory reforms, increased industry collaborations. Additionally, rising awareness about chronic diseases, government incentives to promote research, and the potential for accelerated patient recruitment owing to a higher prevalence of certain chronic diseases are projected to foster market growth.
The prefilled syringes industry in Latin America is experiencing significant growth. The driving factors for Latin America market include the growing prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis. Moreover, the rise in the aging population & their requirement for regular injections for various medical conditions, technological advancement, government initiatives, and expansion of biopharmaceuticals in Latin America are driving the product demand.
The prefilled syringes industry in the Middle East and Africa (MEA) is witnessing steady growth, the region is experiencing rapid expansion, propelled by several key factors. These include rising incidence of chronic diseases, increased awareness about such conditions, favorable governmental policies in selected countries, a diverse and sizable population, and cost advantages in specific economies.
The prefilled syringes market in Saudi Arabia is influenced by several market drivers, contributing to the growth and adoption of these medical devices. Prefilled syringes are becoming more and more popular in Saudi Arabia owing to advances in biologics and vaccines as well as the rising need for efficient and portable drug delivery solutions.
The Kuwait prefilled syringes market is expected to grow over the forecast period. Kuwait represents a favorable investment outlook, with the country focusing on investments in the private sector. Moreover, the country offers prefilled syringes at subsidized rates in the public sector, owing to the plans of the Kuwait Diabetes Society and Ministry of Health. This is expected to drive the demand for prefilled syringes and provide significant growth opportunities for players in the country.
The competitive scenario in the prefilled syringes market is highly competitive, with key players such as West Pharmaceuticals; Stevanato Group; and SCHOTT Pharma AG holding significant positions. The major companies are undertaking several organic as well as inorganic strategies such as new product development, regional expansion, acquisitions, mergers, and collaborations for serving the unmet needs of their customers.
The following are the leading companies in the prefilled syringes market. These companies collectively hold the largest market share and dictate industry trends.
In May 2023, Schott Pharma developed pre-fillable syringes specifically designed for medications that require storage in very cold conditions.
In May 2023, Fresenius Kabi has expanded its Simplist prefilled syringe line with a 100mcg per 2mL dose of Fentanyl Citrate Injection.
In September 2022, Becton Dickinson and Company (BDX) has launched a new, top-of-the-line glass prefillable syringe specifically for vaccines. This innovative product features enhanced specifications for manufacturability, visual quality, contamination control, and overall integrity.
In May 2022, SCHOTT, opens a brand-new facility to manufacture prefillable syringes using innovative polymer materials.
Report Attribute |
Details |
Market size value in 2025 |
USD 8.89 billion |
Revenue forecast in 2030 |
USD 16.73 billion |
Growth rate |
CAGR of 13.50% from 2025 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Report updated |
January 2025 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, material, application, distribution channel, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
BD; Gerresheimer AG; SCHOTT Pharma AG; Stevanato Group; Nipro Corporation; Terumo West pharmaceuticals; Fresenius; Catalent; Aptar Pharma |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global prefilled syringes market report on the basis of type, material, application, distribution channel, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Disposable
Reusable
Material Outlook (Revenue, USD Million, 2018 - 2030)
Glass
Plastic
Application Outlook (Revenue, USD Million, 2018 - 2030)
Vaccines and immunizations
Anaphylaxis
Rheumatoid Arthritis
Diabetes
Autoimmune diseases
Oncology
Others
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Mail Order Pharmacies
Ambulatory Surgery Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global prefilled syringes market size was estimated at USD 8.01 billion in 2024 and is expected to reach USD 8.89 billion in 2025.
b. The global prefilled syringes market is expected to grow at a compound annual growth rate of 13.50% from 2025 to 2030 to reach USD 16.73 billion by 2030.
b. Europe dominated the prefilled syringes market with a share of 37.2% in 2024. This is attributable to growing adoption of prefilled syringes in the UK and development of advanced technologies.
b. Some key players operating in the prefilled syringes market include Gerresheimer AG, Schott Group, BD, Unilife Corporation, Nipro Medical Corporation, Owen Mumford, and Haselmeier AG.
b. Key factors driving the market expansion include technological advancements in prefilled syringes, impact of Covid-19 and growing usage of prefilled syringes owing to its reduced prices per dose.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."